| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Corinne Goldsmith Dickinson Center for Multiple Sclerosis (Dr. Lublin), Mount Sinai Medical Center, New York, NY; Cooper Institute (Dr. Baier), Denver, CO; and University of Nevada, Reno, and Pythagoras, Inc. (Dr. Cutter).
Address correspondence and reprint requests to Dr. F.D. Lublin, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, 5 E. 98 St., New York, NY 10029; e-mail: fred.lublin{at}mssm.edu
Objective: To determine the percentage of patients with residual deficits following multiple sclerosis (MS) exacerbations and the magnitude of those deficits using a database of pooled placebo patients from clinical trials.
Methods: A database of patients assigned to the placebo group in several randomized clinical trials was queried to determine those patients with Expanded Disability Status Scale (EDSS) and Scripps Neurologic Rating Scale assessments prior to, at the time of, and after an acute exacerbation of MS. The extent of deficit present at these time points was compared to determine the acute effect of exacerbations and the degree of persistent disability.
Results: Forty-two percent of patients had residual deficit of at least 0.5 and 28% had residual of 
1.0 EDSS units, at an average of 64 days after an exacerbation. The results were reproduced across subsequent exacerbations and were sustained over time. The subgroup of patients with measurable change in EDSS during the exacerbation had more extensive residual impairment on the follow-up visits. Similar results were seen when the Scripps score was examined.
Conclusion: MS exacerbations produce a measurable and sustained effect on disability.
Received March 21, 2002. Accepted in final form August 18, 2003.
This article has been cited by other articles:
|
|
 |
|
  G. C. Ebers, L. Heigenhauser, M. Daumer, C. Lederer, and J. H. Noseworthy Disability as an outcome in MS clinical trials Neurology, August 26, 2008; 71(9): 624 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Marrie You get what you measure: Evaluating endpoints in MS clinical trials Neurology, August 26, 2008; 71(9): 620 - 621. [Full Text] [PDF]
|
|
|
|
|
|
J. P. Thompson, K. Noyes, E. R. Dorsey, S. R. Schwid, and R. G. Holloway Quantitative risk-benefit analysis of natalizumab Neurology, July 29, 2008; 71(5): 357 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Leone, S. Bonissoni, L. Collimedaglia, F. Tesser, S. Calzoni, A. Stecco, P. Naldi, and F. Monaco Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study Multiple Sclerosis, May 1, 2008; 14(4): 485 - 493. [Abstract] [PDF]
|
|
|
|
|
|
M. Casadio, V. Sanguineti, P. Morasso, and C. Solaro Abnormal sensorimotor control, but intact force field adaptation, in multiple sclerosis subjects with no clinical disability Multiple Sclerosis, April 1, 2008; 14(3): 330 - 342. [Abstract] [PDF]
|
|
|
|
|
|
C. H. Polman, S. C. Reingold, F. Barkhof, P. A. Calabresi, M. Clanet, J. A. Cohen, G. R. Cutter, M. S. Freedman, L. Kappos, F. D. Lublin, et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment Neurology, March 25, 2008; 70(13_Part_2): 1134 - 1140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Cocco, P. Marchi, C. Sardu, P. Russo, A. Paolillo, M. Mascia, M. Solla, J. Frau, L. Lorefice, S. Massole, et al. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis Multiple Sclerosis, September 1, 2007; 13(8): 975 - 980. [Abstract] [PDF]
|
|
|
|
|
|
R. P. Lisak Neurodegeneration in multiple sclerosis: Defining the problem Neurology, May 29, 2007; 68(22_suppl_3): S5 - S12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Khan Can clinical outcomes be used to detect neuroprotection in multiple sclerosis? Neurology, May 29, 2007; 68(22_suppl_3): S64 - S71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. O'Rourke, C. Walsh, G. Antonelli, and M. Hutchinson Predicting beta-interferon failure in relapsing-remitting multiple sclerosis Multiple Sclerosis, April 1, 2007; 13(3): 336 - 342. [Abstract] [PDF]
|
|
|
|
|
|
D. M. Wingerchuk, S. J. Pittock, C. F. Lucchinetti, V. A. Lennon, and B. G. Weinshenker A secondary progressive clinical course is uncommon in neuromyelitis optica Neurology, February 20, 2007; 68(8): 603 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Scolding Stem cell therapy in patients with multiple sclerosis Multiple Sclerosis, November 1, 2006; 12(6): 677 - 678. [PDF]
|
|
|
|
|
|
P. J. Young, C. Lederer, K. Eder, M. Daumer, A. Neiss, C. Polman, L. Kappos, and on behalf of the Sylvia Lawry Centre for Multiple Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis. Neurology, September 12, 2006; 67(5): 804 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S A Trip, P G Schlottmann, S J Jones, D F Garway-Heath, A J Thompson, G T Plant, and D H Miller Quantification of optic nerve head topography in optic neuritis: a pilot study Br. J. Ophthalmol., September 1, 2006; 90(9): 1128 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Correale, M. Fiol, and W. Gilmore The risk of relapses in multiple sclerosis during systemic infections Neurology, August 22, 2006; 67(4): 652 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Frohman, E. Havrdova, F. Lublin, F. Barkhof, A. Achiron, M. K. Sharief, O. Stuve, M. K. Racke, L. Steinman, H. Weiner, et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol, April 1, 2006; 63(4): 614 - 619. [Full Text] [PDF]
|
|
|
|
|
|
F Sellebjerg, C Ross, N Koch-Henriksen, P S. Sorensen, J L Frederiksen, K Bendtzen, and T L Sorensen CD26+CD4+T cell counts and attack risk in interferon-treated multiple sclerosis Multiple Sclerosis, December 1, 2005; 11(6): 641 - 645. [Abstract] [PDF]
|
|
|
|
 |
|
 S M Leary, B Porter, and A J Thompson Multiple sclerosis: diagnosis and the management of acute relapses Postgrad. Med. J., May 1, 2005; 81(955): 302 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Cohen, O. Khan, D. R. Jeffery, K. Bashir, S. A. Rizvi, E. J. Fox, M. Agius, R. Bashir, T. E. Collins, R. Herndon, et al. Identifying and treating patients with suboptimal responses Neurology, December 28, 2004; 63(12_suppl_6): S33 - S40. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. J. Hickman, A. T. Toosy, S. J. Jones, D. R. Altmann, K. A. Miszkiel, D. G. MacManus, G. J. Barker, G. T. Plant, A. J. Thompson, and D. H. Miller A serial MRI study following optic nerve mean area in acute optic neuritis Brain, November 1, 2004; 127(11): 2498 - 2505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Menard and F. D. Lublin Effect of relapses on development of residual deficit in multiple sclerosis Neurology, August 10, 2004; 63(3): 599 - 599. [Full Text] [PDF]
|
|
|
|
|
|
M J Tullman, R J Oshinsky, F D Lublin, and G R Cutter Clinical characteristics of progressive relapsing multiple sclerosis Multiple Sclerosis, August 1, 2004; 10(4): 451 - 454. [Abstract] [PDF]
|
|
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
